Prognostic significance of IKZF1 alteration status in pediatric B-lineage acute lymphoblastic leukemia: A meta-analysis

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 889-891

  Feng, Jianhua ^a   Tang, Yongmin ^a  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IKAROS TRANSCRIPTION FACTOR; IKAROS ZINC FINGER 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL CRISIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; DIPLOIDY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; GENE DELETION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; HIGH RISK PATIENT; HUMAN; LETTER; META ANALYSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT;

HUMANS; IKAROS TRANSCRIPTION FACTOR; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 84879539847     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.723212     Document Type: Letter

References (14)

1. Pui CH, Relling MV, Downing Jr. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
3. Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994; 79: 143-156.
4. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
5. Mullighan C G, Miller C B, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
6. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report. J Clin Oncol 2009; 27: 5202-5207.
7. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identifi cation and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: On behalf of Gruppo Italiano Malattie Ematologiche dell ' Adulto Acute Leuke mi a Working Party (GIMEMA AL WP). Blood 2009; 114: 2159-2167.
8. Tonnelle C, Bardin F, Maroc C, et al. Forced expression of the Ikaros 6 isoform in human placental blood CD34 (+) cells impairs their ability to diff erentiate toward the B-lymphoid lineage. Blood 2001; 98: 2673-2680.
9. Chen I M, Harvey R C, Mullighan C G, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children ' s Oncology Group study. Blood 2012; 119: 3512-3522.
10. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
11. Mullighan C G, S u X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
12. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: A multicenter analysis in Taiwan. Cancer Sci 2011; 102: 1874-1881.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.